Cargando…

Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland

OBJECTIVES: To study patient selection for and persistence with ADP receptor-inhibiting oral antiplatelet (OAP) treatment after acute coronary syndrome (ACS). DESIGN: Observational, retrospective, cohort study linking real-life patient-level register data. SETTING: Nationwide drug usage study using...

Descripción completa

Detalles Bibliográficos
Autores principales: Prami, Tuire, Khanfir, Houssem, Deleskog, Anna, Hasvold, Pål, Kytö, Ville, Reissell, Eeva, Airaksinen, Juhani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129076/
https://www.ncbi.nlm.nih.gov/pubmed/27881527
http://dx.doi.org/10.1136/bmjopen-2016-012604
_version_ 1782470528706019328
author Prami, Tuire
Khanfir, Houssem
Deleskog, Anna
Hasvold, Pål
Kytö, Ville
Reissell, Eeva
Airaksinen, Juhani
author_facet Prami, Tuire
Khanfir, Houssem
Deleskog, Anna
Hasvold, Pål
Kytö, Ville
Reissell, Eeva
Airaksinen, Juhani
author_sort Prami, Tuire
collection PubMed
description OBJECTIVES: To study patient selection for and persistence with ADP receptor-inhibiting oral antiplatelet (OAP) treatment after acute coronary syndrome (ACS). DESIGN: Observational, retrospective, cohort study linking real-life patient-level register data. SETTING: Nationwide drug usage study using data of patients with ACS discharged from hospitals in Finland. PARTICIPANTS: The study population consisted of 54 416 patients (aged ≥18 years) following hospital admission for unstable angina pectoris or myocardial infarction during 2009–2013. Patients were classified as either OAP or non-OAP users based on drug purchases within 7 days of discharge. OUTCOME MEASURES: Initiation of and a 12-month persistence with OAP medication. RESULTS: In total, 49% of patients with ACS received OAP treatment after hospital discharge. Women represented 40% of the population, but only 32% of them became OAP users (adjusted OR for initiation compared with men 0.8; p<0.001). Patients not treated with percutaneous coronary intervention (PCI), elderly and patients with dementia/Alzheimer's disease, atrial fibrillation or warfarin treatment were less likely to be treated with OAP. If initiated, they were less likely to complete the recommended 12 months’ medication (adjusted risk increment >38% and p<0.001 for all). The OAP users showed good compliance with immediate initiation (92% within 1 day of discharge) and high mean medication possession rate (99%). Among OAP users, the usage of other secondary prevention drugs after ACS was more common than in non-OAP-treated patients (difference >20 percentage points for each). CONCLUSIONS: Only half of the patients with ACS received guideline-recommended ADP receptor-inhibiting OAP treatment after hospital discharge, suggesting suboptimal treatment practices. Non-PCI-treated patients and patients with increased age, unstable angina, dementia or atrial fibrillation appear to have the highest risk of deficient treatment with OAPs. OAP users, however, showed good compliance during drug usage.
format Online
Article
Text
id pubmed-5129076
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51290762016-12-02 Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland Prami, Tuire Khanfir, Houssem Deleskog, Anna Hasvold, Pål Kytö, Ville Reissell, Eeva Airaksinen, Juhani BMJ Open Cardiovascular Medicine OBJECTIVES: To study patient selection for and persistence with ADP receptor-inhibiting oral antiplatelet (OAP) treatment after acute coronary syndrome (ACS). DESIGN: Observational, retrospective, cohort study linking real-life patient-level register data. SETTING: Nationwide drug usage study using data of patients with ACS discharged from hospitals in Finland. PARTICIPANTS: The study population consisted of 54 416 patients (aged ≥18 years) following hospital admission for unstable angina pectoris or myocardial infarction during 2009–2013. Patients were classified as either OAP or non-OAP users based on drug purchases within 7 days of discharge. OUTCOME MEASURES: Initiation of and a 12-month persistence with OAP medication. RESULTS: In total, 49% of patients with ACS received OAP treatment after hospital discharge. Women represented 40% of the population, but only 32% of them became OAP users (adjusted OR for initiation compared with men 0.8; p<0.001). Patients not treated with percutaneous coronary intervention (PCI), elderly and patients with dementia/Alzheimer's disease, atrial fibrillation or warfarin treatment were less likely to be treated with OAP. If initiated, they were less likely to complete the recommended 12 months’ medication (adjusted risk increment >38% and p<0.001 for all). The OAP users showed good compliance with immediate initiation (92% within 1 day of discharge) and high mean medication possession rate (99%). Among OAP users, the usage of other secondary prevention drugs after ACS was more common than in non-OAP-treated patients (difference >20 percentage points for each). CONCLUSIONS: Only half of the patients with ACS received guideline-recommended ADP receptor-inhibiting OAP treatment after hospital discharge, suggesting suboptimal treatment practices. Non-PCI-treated patients and patients with increased age, unstable angina, dementia or atrial fibrillation appear to have the highest risk of deficient treatment with OAPs. OAP users, however, showed good compliance during drug usage. BMJ Publishing Group 2016-11-22 /pmc/articles/PMC5129076/ /pubmed/27881527 http://dx.doi.org/10.1136/bmjopen-2016-012604 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Cardiovascular Medicine
Prami, Tuire
Khanfir, Houssem
Deleskog, Anna
Hasvold, Pål
Kytö, Ville
Reissell, Eeva
Airaksinen, Juhani
Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title_full Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title_fullStr Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title_full_unstemmed Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title_short Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from Finland
title_sort clinical factors associated with initiation of and persistence with adp receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: a nationwide cohort study from finland
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129076/
https://www.ncbi.nlm.nih.gov/pubmed/27881527
http://dx.doi.org/10.1136/bmjopen-2016-012604
work_keys_str_mv AT pramituire clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT khanfirhoussem clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT deleskoganna clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT hasvoldpal clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT kytoville clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT reisselleeva clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland
AT airaksinenjuhani clinicalfactorsassociatedwithinitiationofandpersistencewithadpreceptorinhibitingoralantiplatelettreatmentafteracutecoronarysyndromeanationwidecohortstudyfromfinland